Friday March 27, 2020 0 comments
GOLDEN -- PharmaJet, maker of innovative, needle-free injection technology, announced Dr. Marie Mazur has been appointed to its board of directors.
Mazur is a global business executive with more than 30 years of experience growing revenue and profits for major vaccine and pharmaceutical companies.
"We are very pleased to welcome Dr. Mazur to the PharmaJet board of directors,” said Ron Lowy, PharmaJet executive chair.
“Her operational and strategic expertise with major vaccine and pharmaceutical companies as well as pandemic vaccine response solutions is an extraordinary addition to our board."
Since 2006, Mazur held executive roles at the influenza vaccine company Seqirus, which is part of CSL Limited, an $8.4 billion biotechnology company engaged in life-saving innovative products and vaccines.
Most recently Mazur was VP, Pandemic Response Solutions, where she had global commercial responsibility for pandemic and pre-pandemic contracts. During her tenure, Seqirus became global leader in pandemic vaccine response.
In January 2018, she was selected as co-chair of BDPAC (Bio-Defense Policy Advisory Committee) at the Biotechnology Innovation Organization, working with biotechnology company leaders invested in the development and manufacture of medical countermeasures.
Prior to joining CSL, she held successive global commercial leadership positions at GlaxoSmithKline Biologicals, 3M Pharmaceuticals and Sanofi Pasteur. Mazur holds a doctorate in pharmacy and a master's degree in regulatory affairs from Paris (France) University of Pharmacy, and an International Executive Degree in Business Administration from INSEAD.
"I am excited to be joining the board of directors of PharmaJet at this challenging time in the vaccine world,” Mazur said.
“I look forward to using my broad commercial operations and pandemic response solutions experience to help the company build on its global business model."